Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown a positive performance since its inception, with a slight increase in scale and significant trading activity in the early days of 2024 [1][2] Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) closed at a 0.38% increase on January 6, with a trading volume of 1.163 billion yuan [1] - As of January 5, the fund's latest share count was 10.479 billion shares, with a total scale of 8.331 billion yuan, reflecting a 5.50% increase in scale since December 31, 2025 [1] - The fund's management fee is set at 0.50% annually, and the custody fee is 0.10% annually [1] Group 2: Trading Activity - Over the past 20 trading days, the cumulative trading amount for the ETF reached 16.464 billion yuan, with an average daily trading amount of 0.823 billion yuan [1] - In the first two trading days of 2024, the ETF recorded a cumulative trading amount of 2.789 billion yuan, averaging 1.394 billion yuan per day [1] Group 3: Fund Holdings - The top holdings of the Hong Kong Innovative Drug ETF include companies such as BeiGene, CanSino Biologics, and Innovent Biologics, with significant percentages of the fund's total assets allocated to these stocks [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed closely by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2] - Other notable holdings include China National Pharmaceutical Group and Stone Group, with respective allocations of 9.62% and 7.56% [2]

Core Insights - The report from China Merchants Securities International indicates that the pharmaceutical industry will experience differentiated growth by 2026, with chronic diseases remaining the largest driver for the future of the pharmaceutical sector [1] - The report emphasizes that upgrades on the supply side and improvements in the operational quality of representative companies are key strategies for bottom-up stock selection [1] - It highlights that the US and China will engage in more competition and collaboration in the innovative drug sector, with policy disruptions causing fluctuations but not altering the long-term development direction of the industry [1] Industry Focus - The report expresses a positive outlook on the biopharmaceutical sector, identifying key companies such as Novartis, Innovent Biologics, Aileron Therapeutics, Hansoh Pharmaceutical, and CanSino Biologics as industry favorites [1] - Additional recommendations include companies like Healer, China Resources Pharmaceutical, Thermo Fisher Scientific, and Eli Lilly [1]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 5.75% on January 5, with a trading volume of 1.625 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 31, 2025, the fund's shares stood at 10.492 billion, with a total size of 7.896 billion yuan, indicating no change in shares or size year-to-date [1] Group 2 - The ETF's recent trading activity shows a cumulative trading amount of 16.006 billion yuan over the last 20 trading days, with an average daily trading amount of 800 million yuan [1] - The current fund manager, Ma Jun, has managed the fund since its inception, achieving a return of 50.52% during the management period [1] - The ETF's top holdings include companies such as BeiGene, CanSino Biologics, and Innovent Biologics, with significant weightings in the portfolio [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 翰森製藥集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03692 | 說明 | - | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.00001 | HKD | | 200,000 | 本月底法定 ...

Market Performance - The Hang Seng Technology Index increased by 0.09%, while the Hang Seng Index rose by 0.03% [1] - The Hong Kong Technology ETF (159751) saw a gain of 3.9%, and the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 2.42% [1] Sector Performance - The construction products and life sciences tools sectors showed the highest gains [1] - The leisure equipment and supplies, as well as the automotive sectors, experienced the largest declines [1] Individual Stock Performance - Kuaishou-W surged by 11.09%, and Kelun-B rose by 7.84% [1] - Other notable gainers included Innovent Biologics (6.09%), Beike-W (5.43%), New China Life Insurance (5.34%), BeiGene (5.31%), Chow Tai Fook (5.13%), China Resources Land (5.05%), CSPC Pharmaceutical Group (4.83%), PICC Group (4.57%), Hansoh Pharmaceutical (4.5%), and China Pacific Insurance (4.03%) [1] - In contrast, Innovent Biologics saw a decline of 9.42%, and Global New Material International dropped by 12.6% [1] - Nanjing Panda Electronics experienced a significant increase of 39.75%, while Micron Brain Science rose by 19.73% [1]

Investment Rating - The report maintains an "Outperform" rating for the following A-share targets: Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, MicroPort EP MedTech [5][36][8] - The report also maintains an "Outperform" rating for the following H-share targets: Hansoh Pharmaceutical Group, 3SBio, PATEO Biotech, Akeso, and related targets: Innovent Biologics, WuXi AppTec [8][36] Core Insights - The report continues to recommend the innovative drug and device industry and its supply chains, indicating a positive outlook for this sector [1][36] - In December 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 4.1%, while the SHCOMP rose by 2.1%, ranking 26th among Shenwan primary industries [15][37] - The report highlights that the premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 63.2% as of the end of December 2025 [25][37] Summary by Sections A-Share Targets - The report includes a monthly portfolio of A-share targets that outperformed the pharmaceutical index, with a monthly average decline of 1.8% compared to the overall pharmaceutical index decline of 3.9% in December 2025 [11][36] - The top three stock gains in December 2025 were Luyan Pharma (+118.8%), CareRay Digital Medical Technology Co., Ltd. (+36.6%), and Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (+34.0%) [24][37] H-Share Targets - The report notes that the Hong Kong stock pharmaceutical sector also underperformed the market, with the Hang Seng Healthcare index falling by 9.5% and the Hong Kong Biological Technology index falling by 10.6% in December 2025 [26][38] U.S. Market Performance - In December 2025, the U.S. pharmaceutical sector underperformed the market, with the S&P 500 Healthcare Select Sector declining by 1.5% while the S&P 500 fell by only 0.1% [26][39]

Core Viewpoint - Guolian Minsheng Securities initiates coverage on Baiao Saitu (02315) with a "Buy" rating, highlighting the robust growth across its three main business segments and the positive impact of the "Thousand Mice and Ten Thousand Antibodies" initiative on financial performance [1] Group 1: Model Animals - The company dominates the humanized mouse market with over 1,700 strains, contributing significantly to revenue, with sales and licensing expected to generate 257 million yuan (94% of revenue) by H1 2025 [1] - The sales of model animals are projected to grow at a CAGR of 51.6% from 2022 to 2024, with increasing customer repurchase rates [1] - By 2024, overseas sales of model animals are expected to account for 56.4%, with a mature U.S. subsidiary facilitating order acquisition [1] Group 2: Preclinical CRO Services - The preclinical CRO services segment, which extends from model animals, has an overseas revenue share of 79%, benefiting from a recovering investment environment [2] - The pharmacology and efficacy team operates across Beijing, Haimen, and the U.S., having completed over 6,350 drug evaluation projects for approximately 950 global partners by H1 2025 [2] - Revenue for this segment reached 155 million yuan in H1 2025, reflecting a year-on-year growth of over 90% due to increased client numbers driven by industry growth [2] Group 3: Antibody Molecule Transfer/Authorization - The revenue model based on upfront payments, milestones, and sales sharing allows for significant revenue growth as pipelines advance [3] - The "Thousand Mice and Ten Thousand Antibodies" initiative has created a vast array of antibody combinations, reducing R&D time and uncertainty for pharmaceutical companies [3] - By H1 2025, the company has signed 61 transfer/authorization/co-development projects with renowned pharmaceutical firms, with a projected CAGR of 58.3% for this segment from 2022 to 2024 [3]

Group 1 - The core viewpoint of the news is that the A-share and Hong Kong markets are experiencing a collective rise, with the Shanghai Composite Index surpassing 4000 points, indicating positive market sentiment [1] - The Hong Kong Stock Connect innovative drug index increased by 3.85%, with notable individual stock performances such as Zhaoyan New Drug rising over 11% and Tigermed and Kelun-Bio rising over 6% [1] - According to a report by Changjiang Securities, Zhaoyan New Drug is expected to see a 60% year-on-year growth in offshore outsourcing orders in 2024, driven by domestic safety evaluation demand recovery and resource scarcity [1] Group 2 - The China National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, setting a historical record [1] - The total amount of authorized transactions for innovative drugs in China has exceeded $130 billion, with over 150 transactions, also a historical high [1] - Currently, China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [1] Group 3 - The Hong Kong Stock Connect innovative drug ETF managed by Harvest (520970) has a management and custody fee of 0.60% per year, making it suitable for both retail investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

Group 1: Market Performance - The Hong Kong stock market experienced a strong start in 2026, with the Hang Seng Index rising by 2.76% to 26,338.47 points, and the Hang Seng Technology Index increasing by 4% to 5,736.44 points [3] - The Hong Kong Innovation Drug ETF (159570) surged over 5.5%, with a trading volume exceeding 1.6 billion yuan, marking a significant increase compared to the previous trading day [1][3] - As of December 29, 2025, the latest scale of the Hong Kong Innovation Drug ETF reached over 21.4 billion yuan, leading its peers in the same category [1] Group 2: Company News - In a significant development, Insilico Medicine announced a multi-year research collaboration with Servier worth up to $888 million, focusing on oncology drug development [3] - The collaboration will leverage Insilico's AI-driven drug discovery platform, Pharma.AI, in conjunction with Servier's global expertise in oncology [3] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to research achievements [3] Group 3: Industry Trends - In 2025, the Chinese innovative drug industry set a record for outbound licensing transactions, with a total transaction value of $135.655 billion and 157 deals, marking a historical high [5] - The industry is witnessing a diversification in business development (BD) models, with an increasing number of innovative drug companies opting for co-development partnerships with multinational pharmaceutical firms [7][10] - The "Co-Co" (Co-development & Co-commercialization) model is emerging as a significant trend in 2025, exemplified by the $11.4 billion deal between Innovent Biologics and Takeda [11]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown significant upward movement, with a peak increase of over 4% and a trading volume exceeding 258 million yuan, surpassing the previous day's total [1]. Group 1: Market Performance - The ETF opened at 0.516, experiencing a rise of 0.018 (3.61%) during trading [1]. - The trading volume reached 2.58 billion yuan, indicating strong market interest [1]. - The ETF has seen a decline of 7.53% over the past 20 days and 17.04% over the past 60 days, reflecting recent market volatility [1]. Group 2: Industry Insights - The National Medical Products Administration reported that 76 innovative drugs were approved for market in China by 2025, significantly exceeding the 48 approved in 2024, marking a historical high [1]. - The total transaction value for innovative drug licensing in 2025 is projected to exceed 130 billion USD, with over 150 licensing transactions, also a record high [1]. Group 3: Investment Strategy - Analysts from Zhongyou Securities suggest that the maturity of clinical data will be a key driver for the innovative drug market in 2026, with business development (BD) becoming a necessary outcome of enhanced competitiveness for domestic new drugs [2]. - The current period is viewed as an optimal configuration window for the Hong Kong Stock Connect innovative drug sector, following a three-month adjustment that began in September 2025 [2]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has unique advantages, including a focus on pure innovative drug companies and a high concentration of leading firms [2][4]. Group 4: ETF Composition - The top ten holdings in the ETF account for over 72% of its weight, showcasing the dominance of leading innovative drug companies [4]. - Notable companies within the ETF include BeiGene (11.51% weight), Innovent Biologics (10.19%), and China National Pharmaceutical Group (9.47%) [4]. Group 5: Alternative Investment Options - For investors seeking to mitigate volatility while still focusing on innovative drugs, the market offers the only ETF (562050) that combines innovative drugs with traditional Chinese medicine, providing a balanced approach [4].